{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:09:50Z","timestamp":1778602190908,"version":"3.51.4"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpm-2025-0156_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aim to clarify the association and strength of association between antiphospholipid syndrome (APS) and adverse pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0156_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study included an analysis of 191 hospitalized singleton pregnant women with APS and 984 healthy singleton pregnant women at Obstetrics and Gynecology Hospital Affiliated to Fudan University from July 2017 to September 2023. The exposure factor was diagnosed as antiphospholipid syndrome, and the main outcomes were adverse pregnancy outcomes, including miscarriage, preterm birth, low birth weight, gestational hypertension, and eclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0156_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis indicated that the odds ratio (OR) for miscarriage in APS patients was 2.50 (95\u202f% CI, 1.025\u00a0\u00b1\u00a015.794; p=0.046), for preterm birth was 2.8 (95\u202f% CI, 1.025\u00a0\u00b1\u00a015.794; p=0.046), for low birth weight was 2.28 (95\u202f% CI, 1.025\u00a0\u00b1\u00a015.794; p=0.046), and for fetal growth restriction was OR=2.48 (1.45, 4.23) p&lt;0.05. The OR for preeclampsia was 1.00, and for gestational hypertension was 0.96, p&gt;0.05. After adjustment for confounders of age and BMI confounders, the odds ratio (OR) for miscarriage was 2.50 (95\u202f% CI: 1.52\u20134.11) p&lt;0.05. Preterm birth was 2.89 (95\u202f% CI: 1.79\u20134.65) p&lt;0.05, low birth weight was 2.28 (95\u202f% CI: 1.52\u20133.55) p&lt;0.05, intrauterine growth restriction was 2.48 (95\u202f% CI: 1.45\u20134.23) p&lt;0.05. The OR of preeclampsia was 1.00 (95\u202f% CI: 0.59\u20131.71) p&gt;0.05, and that of pregnancy-induced hypertension was 0.96 (95\u202f% CI: 0.53\u20131.75) p&gt;0.05. After adjustment for confounders of age, BMI, eclampsia and diabetes, the OR for preterm infants were 3.06 (95\u202f% CI: 1.87\u20135.00) p&lt;0.05, and those of low birth weight infants were 2.55 (95\u202f% CI: 1.49\u20134.37) p&lt;0.05. After adjustment for confounders of age, BMI, diabetes, eclampsia, and gestational week, the OR for low birth weight infants was 2.02 (95\u202f% CI: 1.26\u20133.26) p&lt;0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpm-2025-0156_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antiphospholipid syndrome was significantly associated with the risk of miscarriage, preterm birth, low birth weight, and intrauterine growth restriction as adverse pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpm-2025-0156","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:57:14Z","timestamp":1764143834000},"page":"515-521","source":"Crossref","is-referenced-by-count":0,"title":["The association of antiphospholipid syndrome under medical treatment with adverse pregnancy outcomes"],"prefix":"10.1515","volume":"54","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[{"name":"66281 Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjie","family":"Xiang","sequence":"additional","affiliation":[{"name":"66281 Ruijin Hospital, Shanghai Jiaotong University School of Medicine , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026051215133571930_j_jpm-2025-0156_ref_001","doi-asserted-by":"crossref","unstructured":"Jesse, Y, Dabit, MO, Valenzuela-Almada, S, Vallejo-Ramos, Duarte-Garc\u00eda, A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep 2022;23:0. https:\/\/doi.org\/10.1007\/s11926-021-01038-2.","DOI":"10.1007\/s11926-021-01038-2"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_002","doi-asserted-by":"crossref","unstructured":"Scambi, C, Ugolini, S, Tonello, M, Bortolami, O, De Franceschi, L, Castagna, A, et al.. Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome. Am J Reprod Immunol 2019;82:e13185. https:\/\/doi.org\/10.1111\/aji.13185.","DOI":"10.1111\/aji.13185"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_003","doi-asserted-by":"crossref","unstructured":"Jiayang, J, Xue, X, Lei, H. Thrombocytopenia in the first trimester predicts adverse pregnancy outcomes in obstetric antiphospholipid syndrome. Front Immunol 2022;13:971005.","DOI":"10.3389\/fimmu.2022.971005"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_004","doi-asserted-by":"crossref","unstructured":"Latino, JO, Udry, S, Aranda, F, Wingeyer, SP, Romero, DSF, Belizna, C, et al.. Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine. Lupus 2020;29:1736\u201342. https:\/\/doi.org\/10.1177\/0961203320952850.","DOI":"10.1177\/0961203320952850"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_005","doi-asserted-by":"crossref","unstructured":"Urban, ML, Bettiol, A, Mattioli, I, Emmi, G, Di Scala, G, Avagliano, L, et al.. Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. Intern Emerg Med 2021;16:1357\u201367. https:\/\/doi.org\/10.1007\/s11739-020-02609-4.","DOI":"10.1007\/s11739-020-02609-4"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_006","doi-asserted-by":"crossref","unstructured":"Miyakis, S, Lockshin, MD, Atsumi, T, Branch, D, Brey, R, Cervera, R, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J\u00a0Thromb Haemostasis 2006;4:295\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x.","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_007","unstructured":"Rheumatology Branch of Chinese Medical Association. Guidelines for diagnosis and treatment of antiphospholipid syndrome. Chin J Hematol 2011;15:407\u201310. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-7480.2011.06.012."},{"key":"2026051215133571930_j_jpm-2025-0156_ref_008","unstructured":"Newborn biometry to Intergrowth-21st standards\/references. [Accessed 11 Aug 2021]. http:\/\/intergrowth21.ndog.ox.ac.uk\/."},{"key":"2026051215133571930_j_jpm-2025-0156_ref_009","unstructured":"Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists\u2019 task force on hypertension in pregnancy. Obstet Gynecol 2013;122:1122\u201331."},{"key":"2026051215133571930_j_jpm-2025-0156_ref_010","unstructured":"Jaume, AR, Enrique, EV, Raquel, FO. The european registry on obstetric antiphospholipid syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev 2019;18:0."},{"key":"2026051215133571930_j_jpm-2025-0156_ref_011","doi-asserted-by":"crossref","unstructured":"Jie, Z, Ge, Z, Liqiong, C. The relation of anti-phosphatidylserine\/prothrombin antibodies and premature rupture of membranes: a retrospective cohort study. J\u00a0Reprod Immunol 2024;167:0.","DOI":"10.1016\/j.jri.2024.104421"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_019","doi-asserted-by":"crossref","unstructured":"Schreiber, K, Hunt, BJ. Pregnancy and antiphospholipid syndrome. Semin Thromb Hemost 2016;42:780\u20138. https:\/\/doi.org\/10.1055\/s-0036-1592336.","DOI":"10.1055\/s-0036-1592336"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_013","doi-asserted-by":"crossref","unstructured":"Kim, YM, Seong, J, Kim, JH, Nam, G, Kim, GJ, Cha, HH, et al.. Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study). BMJ Open 2024;14:e081610. https:\/\/doi.org\/10.1136\/bmjopen-2023-081610.","DOI":"10.1136\/bmjopen-2023-081610"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_014","doi-asserted-by":"crossref","unstructured":"Simard, JF, Liu, EF, Rector, A, Cantu, M, Chakravarty, E, Druzin, M, et al.. Hydroxychloroquine and pre-eclampsia in a diverse cohort of women with systemic lupus erythematosus. Arthritis Care Res 2024;76:1390\u20135. https:\/\/doi.org\/10.1002\/acr.25386.","DOI":"10.1002\/acr.25386"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_012","doi-asserted-by":"crossref","unstructured":"Mayer-Pickel, K, Nanda, M, Gajic, M, Cervar-Zivkovic, M. Preeclampsia and the antiphospholipid syndrome. Biomedicines 2023;11:2298. https:\/\/doi.org\/10.3390\/biomedicines11082298.","DOI":"10.3390\/biomedicines11082298"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_015","doi-asserted-by":"crossref","unstructured":"Knight, JS, Kanthi, Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol 2022;44:0. https:\/\/doi.org\/10.1007\/s00281-022-00916-w.","DOI":"10.1007\/s00281-022-00916-w"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_016","doi-asserted-by":"crossref","unstructured":"Eleni, X, Tektonidou, MG. An update on antiphospholipid syndrome. Curr Rheumatol Rep 2022;23:0. https:\/\/doi.org\/10.1007\/s11926-021-01051-5.","DOI":"10.1007\/s11926-021-01051-5"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_017","doi-asserted-by":"crossref","unstructured":"Venturelli, V, Maranini, B, Tohidi-Esfahani, I, Isenberg, DA, Cohen, H, Efthymiou, M. Can complement activation be the missing link in antiphospholipid syndrome? Rheumatology 2024. https:\/\/doi.org\/10.1093\/rheumatology\/keae178.","DOI":"10.1093\/rheumatology\/keae178"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_018","doi-asserted-by":"crossref","unstructured":"Devreese, KMJ. Thrombosis in antiphospholipid syndrome: current perspectives and challenges in laboratory testing for antiphospholipid antibodies. Semin Thromb Hemost 2024;0:0. https:\/\/doi.org\/10.1055\/s-0044-1791699.","DOI":"10.1055\/s-0044-1791699"},{"key":"2026051215133571930_j_jpm-2025-0156_ref_020","doi-asserted-by":"crossref","unstructured":"Vornic, I, Buciu, V, Furau, CG, Gaje, PN, Ceausu, RA, Dumitru, CS, et al.. Oxidative stress and placental pathogenesis: a contemporary overview of potential biomarkers and emerging therapeutics. Int J Mol Sci 2024;25:12195. https:\/\/doi.org\/10.3390\/ijms252212195.","DOI":"10.3390\/ijms252212195"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0156\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0156\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:20:18Z","timestamp":1778599218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpm-2025-0156\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,22]]},"published-print":{"date-parts":[[2026,3,26]]}},"alternative-id":["10.1515\/jpm-2025-0156"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2025-0156","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]}}}